Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) R&D Finds Lack of Adverse Chemical Byproducts in Manufacture of Drug Delivery Compositions
- Lexaria Bioscience is involved in the research and improvement of its trademarked DehydraTECH technology, which enhances the bioavailability of some legal drug substances used by consumers
- The technology provides a rapid-on, rapid-off effect that may be effectively used in cannabis-infused edibles and beverages as an alternative to mind-altering substances such as alcohol and cannabis
- New research has boosted Lexaria’s hopes, with findings that show no adverse NME chemical compositions were formed in several rounds of in-depth testing
- The company recently formed a collaboration with Hill Street Beverage Company to make cannabis-infused alternatives to alcoholic beverages
- By 2024, cannabis-infused beverage sales are expected to reach $1.4 billion
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has announced the completion of a research agreement that is moving the company forward as it investigates market opportunities that would use Lexaria’s patented DehydraTECH technology to aid biological absorption of substances such as cannabinoids, nicotine and ibuprofen.
Under a master collaborative research agreement with the National Research Council of Canada (NRC), Lexaria focused on technical aspects of DehydraTECH’s drug delivery processes for speeding up lipophilic active ingredient compositions’ bioavailability to see if the technology caused the formation of a new molecular entity (NME) during activation, according to a company news release (http://nnw.fm/4XWje).
The creation of an NME would likely have burdened Lexaria’s research program with additional testing and regulation to establish the NME’s safety for human consumption under the oversight of the U.S. Food and Drug Administration (FDA) and Health Canada.
“The company is very pleased to report that all evidence aligns that no covalent-bonded NME is created with Lexaria’s technology,” the news release states.
The collaboration with the NRC analyzed 33 formulations using DehydraTECH technology out of more than 50 that were prepared. In addition to the drug substances analyzed in-depth, the research tested long chain fatty acid and medium chain triglyceride oils alone and in combination.
The testing demonstrated no shift in the spectral positioning of the API pharmaceuticals’ molecular construction for all formulations tested, which provided nearly incontrovertible evidence of a lack of any covalent-bonded NME, according to the company.
Lexaria also noted that the National Research Council of Canada study discovered the remarkable stability of DehydraTECH technology, even under highly acidic conditions. “Other formulation technologies by third parties that have not been tested for pH stability cannot be relied upon to deliver stable quantities of the API in question within an acidic beverage,” the news release states. “Since mildly acidic formulas are used in the vast majority of beverages sold in North America today, pH stability testing is a necessary aspect of safely delivering cannabinoids within popular beverage formats and Lexaria’s technology is now proven capable of doing so.”
Lexaria, through its working relationship with the NRC, continues to pursue other objectives, such as determining what interactions take place at the molecular level between nicotine polacrilex formulations and DehydraTECH’s methodology in order to continually improve on DehydraTECH and expand scientific understanding of its processes.
Lexaria announced July 24 that it will collaborate with alcohol-free and cannabis-infused beer and wine maker Hill Street Beverage Company Inc. (TSX.V: BEER) in creating a new brand of tetrahydrocannabinol (THC) and/or cannabidiol (CBD)-infused products as edible and beverage consumption of cannabis becomes nationally legal in Canada later this year (http://nnw.fm/EjN37).
Market analysts at Zenith Global forecast that the U.S. market for cannabis- and hemp-infused drinks will rocket to over $1.4 billion by 2024, reflecting a growing interest in alternatives to alcoholic beverages with a potential wellness aspect to them. Lexaria’s technology is also attractive because it provides a relatively rapid-on, rapid-off effect that reduces or eliminates the potential hazards of alcohol that carry over into other daily activities (http://nnw.fm/LdP4g).
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria Bioscience is involved in the research and improvement of its trademarked DehydraTECH technology, which enhances the bioavailability of some legal drug substances used by consumers
- The technology provides a rapid-on, rapid-off effect that may be effectively used in cannabis-infused edibles and beverages as an alternative to mind-altering substances such as alcohol and cannabis
- New research has boosted Lexaria’s hopes, with findings that show no adverse NME chemical compositions were formed in several rounds of in-depth testing
- The company recently formed a collaboration with Hill Street Beverage Company to make cannabis-infused alternatives to alcoholic beverages
- By 2024, cannabis-infused beverage sales are expected to reach $1.4 billion
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has announced the completion of a research agreement that is moving the company forward as it investigates market opportunities that would use Lexaria’s patented DehydraTECH technology to aid biological absorption of substances such as cannabinoids, nicotine and ibuprofen.
Under a master collaborative research agreement with the National Research Council of Canada (NRC), Lexaria focused on technical aspects of DehydraTECH’s drug delivery processes for speeding up lipophilic active ingredient compositions’ bioavailability to see if the technology caused the formation of a new molecular entity (NME) during activation, according to a company news release (http://nnw.fm/4XWje).
The creation of an NME would likely have burdened Lexaria’s research program with additional testing and regulation to establish the NME’s safety for human consumption under the oversight of the U.S. Food and Drug Administration (FDA) and Health Canada.
“The company is very pleased to report that all evidence aligns that no covalent-bonded NME is created with Lexaria’s technology,” the news release states.
The collaboration with the NRC analyzed 33 formulations using DehydraTECH technology out of more than 50 that were prepared. In addition to the drug substances analyzed in-depth, the research tested long chain fatty acid and medium chain triglyceride oils alone and in combination.
The testing demonstrated no shift in the spectral positioning of the API pharmaceuticals’ molecular construction for all formulations tested, which provided nearly incontrovertible evidence of a lack of any covalent-bonded NME, according to the company.
Lexaria also noted that the National Research Council of Canada study discovered the remarkable stability of DehydraTECH technology, even under highly acidic conditions. “Other formulation technologies by third parties that have not been tested for pH stability cannot be relied upon to deliver stable quantities of the API in question within an acidic beverage,” the news release states. “Since mildly acidic formulas are used in the vast majority of beverages sold in North America today, pH stability testing is a necessary aspect of safely delivering cannabinoids within popular beverage formats and Lexaria’s technology is now proven capable of doing so.”
Lexaria, through its working relationship with the NRC, continues to pursue other objectives, such as determining what interactions take place at the molecular level between nicotine polacrilex formulations and DehydraTECH’s methodology in order to continually improve on DehydraTECH and expand scientific understanding of its processes.
Lexaria announced July 24 that it will collaborate with alcohol-free and cannabis-infused beer and wine maker Hill Street Beverage Company Inc. (TSX.V: BEER) in creating a new brand of tetrahydrocannabinol (THC) and/or cannabidiol (CBD)-infused products as edible and beverage consumption of cannabis becomes nationally legal in Canada later this year (http://nnw.fm/EjN37).
Market analysts at Zenith Global forecast that the U.S. market for cannabis- and hemp-infused drinks will rocket to over $1.4 billion by 2024, reflecting a growing interest in alternatives to alcoholic beverages with a potential wellness aspect to them. Lexaria’s technology is also attractive because it provides a relatively rapid-on, rapid-off effect that reduces or eliminates the potential hazards of alcohol that carry over into other daily activities (http://nnw.fm/LdP4g).
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
